Trial Profile
An Open-Label, Long-Term Treatment Study to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane With Subjective Tinnitus
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Neramexane (Primary)
- Indications Tinnitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OLLTT
- 02 Apr 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 20 Mar 2012 Planned patients number (840) added as reported by European Clinical Trials Database.
- 16 Mar 2012 Planned end date changed from 1 Jul 2012 to 1 Dec 2011 as reported by ClinicalTrials.gov.